PIN46 VAX-THE-NATION: A BUDGET IMPACT ANALYSIS OF INCREASED MEASLES, MUMPS AND RUBELLA VACCINATION UPTAKE IN THE US

Value in Health ◽

10.1016/j.jval.2019.04.916 ◽

2019 ◽

Vol 22 ◽

pp. S201-S202

Author(s):

C. Painter ◽

T. Curteis ◽

E. Walker ◽

N.C. Hearmon

Keyword(s):

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Vaccination Uptake ◽

The Us ◽

Rubella Vaccination

Download Full-text

Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US

Journal of Medical Economics ◽

10.1080/13696998.2018.1557199 ◽

2019 ◽

Vol 22 (2) ◽

pp. 187-195 ◽

Author(s):

Lei Wu ◽

Lixian Zhong

Keyword(s):

Ovarian Cancer ◽

Maintenance Treatment ◽

Impact Analysis ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Budget Impact Analysis ◽

Platinum Sensitive ◽

Download Full-text

Alemtuzumab Budget Impact Analysis in Relapsing-Remitting Multiple Sclerosis in the US

Value in Health ◽

10.1016/j.jval.2015.03.1637 ◽

2015 ◽

Vol 18 (3) ◽

pp. A280

Author(s):

C. Celestin ◽

T. Wandstrat ◽

C.I. Coleman

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Relapsing Remitting ◽

The Us ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Budget Impact Analysis of Avelumab in Patients with Metastatic Merkel Cell Carcinoma in The US

Value in Health ◽

10.1016/j.jval.2017.08.153 ◽

2017 ◽

Vol 20 (9) ◽

pp. A424

Author(s):

M Bharmal ◽

SP D'Angelo ◽

H Phatak

Keyword(s):

Cell Carcinoma ◽

Merkel Cell Carcinoma ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Merkel Cell ◽

Download Full-text

Correction to: Lane et al., Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.

Journal of Medical Economics ◽

10.1080/13696998.2018.1452510 ◽

2018 ◽

Vol 21 (5) ◽

pp. 542-542

Author(s):

Ws Lane ◽

James Weatherall ◽

Jens Gundgaard ◽

Richard F. Pollock

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Impact Analysis ◽

Budget Impact ◽

Insulin Degludec ◽

Budget Impact Analysis ◽

Download Full-text

Budget Impact Analysis of Niraparib and Olaparub As Maintenance Therapy for Platinum Sensitive, Recurrent Ovarian Cancer In The US

Value in Health ◽

10.1016/j.jval.2018.04.132 ◽

2018 ◽

Vol 21 ◽

pp. S22

Author(s):

L Wu ◽

L Zhong

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Impact Analysis ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Budget Impact Analysis ◽

Platinum Sensitive ◽

Download Full-text

CE3 INTEGRATED ECONOMIC EVALUATION OF ENFUVIRTIDE (ENF) IN THE US USING A COMBINATION OF COST-EFFECTIVENES ANALYSIS (CEA) AND BUDGET IMPACT ANALYSIS (BIA) TO ENHANCE HEALTH CARE DECISION-MAKING

Value in Health ◽

10.1016/s1098-3015(10)61605-1 ◽

2003 ◽

Vol 6 (6) ◽

pp. 625

Author(s):

J Hornberger ◽

M Covington ◽

R Luo ◽

Z Wang

Keyword(s):

Health Care ◽

Decision Making ◽

Economic Evaluation ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Health Care Decision ◽

The Us ◽

Download Full-text

Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables

Journal of Medical Economics ◽

10.1080/13696998.2017.1384383 ◽

2017 ◽

Vol 21 (2) ◽

pp. 144-151 ◽

Author(s):

Wendy S. Lane ◽

James Weatherall ◽

Jens Gundgaard ◽

Richard F. Pollock

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Impact Analysis ◽

Budget Impact ◽

Insulin Degludec ◽

Budget Impact Analysis ◽

Download Full-text

P10.04 A Budget Impact Analysis for Treatment with Ramucirumab Plus Erlotinib in Metastatic EGFR-Mutated NSCLC in the US

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.493 ◽

2021 ◽

Vol 16 (3) ◽

pp. S322-S323

Author(s):

J. Nilsson ◽

K. Winfree ◽

C. Molife ◽

D. Bhattacharyya ◽

Y. D'Yachova ◽

...

Keyword(s):

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

The Us ◽

Download Full-text

Cost-utility Analysis, Cost-effectiveness Analysis, Budget Impact Analysis

Case Medical Research ◽

10.31525/ct1-nct04283565 ◽

2020 ◽

Author(s):

Keyword(s):

Cost Effectiveness ◽

Impact Analysis ◽

Budget Impact ◽

Cost Utility ◽

Cost Effectiveness Analysis ◽

Cost Utility Analysis ◽

Budget Impact Analysis ◽

Utility Analysis ◽

Effectiveness Analysis

Download Full-text

PCN118 Budget IMPACT Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor ACUTE Lymphoblastic Leukemia in the Netherlands

Value in Health ◽

10.1016/j.jval.2020.08.255 ◽

2020 ◽

Vol 23 ◽

pp. S444

Author(s):

I. van Oostrum ◽

K. De Lameillieure ◽

T.A. Russell-Smith

Keyword(s):

Acute Lymphoblastic Leukemia ◽

The Netherlands ◽

B Cell ◽

Impact Analysis ◽

Budget Impact ◽

Lymphoblastic Leukemia ◽

Budget Impact Analysis ◽

Cell Precursor ◽

Inotuzumab Ozogamicin

Download Full-text